What is the recommended dosing schedule for ramipril (Altace) in adults with hypertension or heart failure, including dose adjustments for elderly patients, low blood pressure, and renal impairment?

Ramipril (Altace) Dosing

For heart failure, start ramipril at 1.25–2.5 mg once daily and titrate to a maintenance dose of 2.5–5 mg twice daily (target 5 mg BID). 1 For post-MI patients with LV dysfunction, start at 2.5 mg twice daily and titrate to 5 mg twice daily. 1

Heart Failure Dosing

• Initiating dose: 1.25–2.5 mg once daily 1
• Maintenance dose: 2.5–5 mg twice daily (BID) 1
• Target dose from trials: 5 mg BID (as used in the AIRE study) 1

Titration Protocol for Heart Failure

• Start with low-dose administration for one week 1
• Check serum potassium and creatinine after 5–7 days and titrate accordingly 1
• Recheck every 5–7 days until potassium values are stable 1
• Build up to maintenance dosages shown to be effective in large trials 1
• Check blood pressure, renal function, and electrolytes 1–2 weeks after each dose increment, at 3 months, and subsequently at regular 6-month intervals 1

Post-Myocardial Infarction Dosing

• Starting dose: 2.5 mg twice daily 1
• Target dose: 5 mg twice daily 1
• Should be administered within the first 24 hours to all patients with STEMI with anterior location, heart failure, or ejection fraction ≤0.40, unless contraindicated 1

Hypertension Dosing

• Starting dose: 2.5–5 mg once daily 2, 3
• Usual effective range: 5–10 mg once daily 2, 3
• Maximum dose: 20 mg daily 3
• Daily doses of 5 mg or more can control blood pressure over a 24-hour period 2

Dose Adjustments for Special Populations

Renal Impairment

• CrCl <30 mL/min: Initial dose 1.25 mg daily; maximum dose must not exceed 5 mg/day 1
• Ramipril is effective and well-tolerated in patients with various degrees of renal failure 4
• Monitor serum creatinine closely; if renal function deteriorates substantially, stop treatment 1
• Plasma ramipril levels are higher in patients with severe renal failure, though blood pressure response remains similar 4

Elderly Patients

• No specific dose reduction required based on age alone 5
• Ramipril shows similar efficacy and safety in elderly patients (66–87 years) compared to younger patients (17–65 years) 5
• Starting dose of 2.5 mg is safe in elderly patients with no increased risk of first-dose hypotension 6
• Use caution in patients aged >85 years, particularly those with symptomatic orthostatic hypotension or moderate-to-severe frailty 1

Low Blood Pressure

• Consider reducing or withholding diuretics for 24 hours before initiation 1
• It may be advisable to start treatment in the evening when supine to minimize the potential negative effect on blood pressure 1
• When initiated in the morning, supervision for several hours with blood pressure control is advisable in risk patients with renal dysfunction or low blood pressure 1
• Avoid in patients with systolic BP <90 mm Hg or if systolic BP is >30 mm Hg below baseline 1
• Even in patients with low blood pressure (systolic BP ≤100 mmHg), guideline-directed medical therapy including ACE inhibitors is associated with improved survival 7

Timing of Administration

• Bedtime dosing is significantly more effective than morning dosing for controlling nighttime blood pressure without loss of daytime efficacy 8
• Bedtime administration increases the proportion of patients with controlled ambulatory blood pressure from 43% to 65% 8
• This is clinically important because nighttime blood pressure is a more relevant marker of cardiovascular risk than diurnal values 8

Important Monitoring Parameters

• Contraindications: Bilateral renal artery stenosis, history of angioedema with previous ACE inhibitor therapy, pregnancy 1
• Avoid: Potassium-sparing diuretics during initiation, NSAIDs and COX-2 inhibitors 1
• Monitor for: Hypotension, renal failure, hyperkalemia 1
• Review the need for and dose of diuretics and vasodilators before starting ramipril 1

Common Pitfalls

• Do not combine ramipril with ARBs and aldosterone antagonists (triple therapy is potentially harmful) 1
• Angioedema occurs in <1% of patients but is more frequent in Black patients; if it occurs, avoid all ACE inhibitors for the patient's lifetime 1
• Up to 20% of patients experience ACE inhibitor-induced cough 1